Personalized Medicine

Foley’s Personalized Medicine attorneys counsel you on matters involving the development and IP protection of genetic testing procedures and mobile health care, payer coverage issues, and patient privacy protection, among many others.

Our clients operating in the personalized medicine space recognize the rewards in bringing new products to market, while acknowledging some of the uncertainties and risks involved as regulatory and policy issues remain unanswered. Foley’s Personalized Medicine attorneys offer experience in cross-disciplinary areas, including business and private equity, regulatory, privacy, reimbursement, health care, and IP to help you as you do business in this emerging space.

Foley's Personalized Medicine Bulletin provides insight on the latest developments on various related topics.

Related Services

Insights

2019 FDA Precision Medicine Approvals: Progress At FDA
24 February 2020
Personalized Medicine Bulletin
2020 Business of Personalized Medicine Summit: Break Through to Solutions in the Birthplace of Biotechnology
18 February 2020
Personalized Medicine Bulletin
USPTO Updates Guidance on Patent-Eligibility of Personalized Therapy
12 November 2019
Personalized Medicine Bulletin
Personalized Cancer Therapy Found Nonobvious
15 October 2019
Personalized Medicine Bulletin
Konski Quoted on Myriad Patent Case
10 October 2014
Bloomberg BNA’s Patent, Trademark & Copyright Journal
Konski Quoted on Patent Office's Post-Myriad Guide
13 March 2014
FDA Week
Brinckerhoff Quoted on Mayo v. Prometheus
20 March 2012
Reuters
Foley Attorneys File Amicus Brief Related to ACLU v. Myriad
11 January 2010